Form 4: Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares

Director John Kiely of Amneal Pharmaceuticals sold 50,000 shares of Class A Common Stock at an average price of $7.59 on May 12, 2025.

Summary

• On May 12, 2025, John Kiely, a director of Amneal Pharmaceuticals, sold 50,000 shares of Class A Common Stock.
• The shares were sold at a weighted average price of $7.59, with individual transactions ranging from $7.49 to $7.67 per share.
• Following the transaction, Kiely directly owns 257,433 shares of Amneal Pharmaceuticals.
• The sale was reported on a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. It doesn't inherently indicate positive or negative sentiment towards the company.

Industry Context

This Form 4 filing indicates insider trading activity, which is closely monitored by investors as it can provide insights into management's perspective on the company's current valuation and future prospects. However, without additional context, it's difficult to determine the specific reasons behind the stock sale.

Stakeholder Impact

• The sale of shares by a director could potentially influence investor sentiment, although the impact is likely to be minimal given the size of the transaction relative to the company's overall market capitalization.

Key Dates

Keywords

Amneal Pharmaceuticals, AMRX, John Kiely, stock sale, Form 4, director, insider trading